Disease Risk & Prevention

Cancer Detection Redefined: SuperDNA’s Liquid Biopsy for Early Multi-Cancer Screening

Liquid Biopsy in Malaysia: A Game-Changer for Early Cancer Detection

Cancer is one of Malaysia’s leading causes of death. But early detection can change everything—enabling less invasive treatment, higher survival rates, and better long-term outcomes.

At SuperDNA, we’re proud to be the first company in Malaysia to offer Whole Genome Sequencing (WGS) for advanced genetic testing. With our cutting-edge liquid biopsy technology, we offer a non-invasive, highly accurate method to detect multiple types of cancer at its earliest—and most treatable—stages.


🔍 What Is a Liquid Biopsy?

A liquid biopsy is a simple blood test that detects signs of cancer by analyzing materials released into your bloodstream by tumors. These include:

  • Circulating Tumor DNA (ctDNA) – small fragments of DNA shed by cancer cells

  • Circulating Tumor Cells (CTCs) – whole cancer cells that break off and enter the bloodstream

Liquid biopsy enables early cancer detection, treatment monitoring, and recurrence tracking—all without invasive procedures.


⚖️ ctDNA vs. CTCs: What’s the Difference?

While both biomarkers are used in cancer detection, ctDNA has emerged as the more reliable and practical choice for routine screening.

🔬 Comparison Table: ctDNA vs. CTCs

Feature CTCs (Circulating Tumor Cells) ctDNA (Circulating Tumor DNA)
What it is Whole cancer cells in the blood DNA fragments from tumor cells
Detection in early cancer Limited – often undetectable High – detectable even in early stages
Stability Fragile and short-lived More stable and easier to analyze
Lab complexity Requires specialized processing Scalable with modern sequencing
Cost Higher due to complexity More affordable and widely used
Best used for Advanced cancer profiling Early detection, mutation analysis, recurrence tracking

Because ctDNA offers higher sensitivity and stability, SuperDNA’s Multi-Cancer Early Detection Test focuses on ctDNA analysis—making it ideal for real-world application in Malaysia’s healthcare landscape. Find out more about Cancer Detect here.


💡 Real-World Applications of Liquid Biopsy

✅ 1. Multi-Cancer Early Detection (MCED)

One test can detect multiple types of cancer, including but not limited to:

  • Breast

  • Lung

  • Colorectal

  • Prostate

  • Liver

  • Ovarian

  • Pancreatic

This makes liquid biopsy ideal for annual cancer screening, especially for individuals with family history or elevated risk.

✅ 2. Pre-Symptomatic Detection

Studies show that ctDNA can reveal cancer-related mutations before symptoms appear, as early as stage 1, enabling life-saving early intervention.

✅ 3. Monitoring Treatment & Recurrence

Liquid biopsy can track cancer treatment progress and detect relapse earlier than traditional scans, enabling faster, more targeted responses.


🧬 Why Choose SuperDNA for Cancer Detection?

As the pioneer of Whole Genome Sequencing in Malaysia, SuperDNA combines clinical-grade technology with in-house lab expertise to deliver:

  • High-sensitivity liquid biopsy testing

  • Accurate analysis of circulating tumor DNA

  • Non-invasive sample collection (blood or saliva)

  • Comprehensive reporting + expert consultation

Whether you’re looking to screen proactively, confirm family risk, or monitor past conditions, SuperDNA offers trusted, science-backed solutions tailored to you.


🧭 Who Should Consider a Liquid Biopsy?

  • Individuals with a family history of cancer

  • Those seeking non-invasive annual screening

  • Cancer survivors monitoring for recurrence

  • Anyone focused on preventive health and early intervention


🧪 How It Works

  1. Order online at mysuperdna.com/shop

  2. Receive a blood sample collection kit

  3. Return your sample via courier or clinic visit

  4. Get your results and report within 14–21 working days

  5. Review with our expert consultants


🌱 Take Control of Your Health Today

Early detection saves lives. With SuperDNA’s liquid biopsy and WGS-powered testing, you no longer need to wait for symptoms to act.

Explore our best-in-class genetic cancer screening options today:

References

  1. Ignatiadis, M., Sledge, G.W. and Jeffrey, S.S., 2021. Liquid biopsy enters the clinic—implementation issues and future challenges. Nature Reviews Clinical Oncology, 18(5), pp.297-312.
  2. American Cancer Society. (2021). Cancer Facts & Figures 2021. Atlanta: American Cancer Society.
  3. Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R. (2019). Liquid biopsy in breast cancer: A comprehensive review. Clinical Genetics, 95(6), 643-660.
  4. Shishido, S. N., Masson, R., Xu, L., Welter, L., Prabakar, R. K., D’Souza, A., … & Kuhn, P. (2022). Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib. NPJ Breast Cancer, 8(1), 22.
  5. Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020). Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 1(3), 276-290.
  6. Zhu, J. W., Charkhchi, P., & Akbari, M. R. (2022). Potential clinical utility of liquid biopsies in ovarian cancer. Molecular Cancer, 21(1), 114.
  7. Wang, Y., Li, L., Cohen, J. D., Kinde, I., Ptak, J., Popoli, M., … & Olsson, L. (2019). Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncology, 5(8), 1118-1123.
  8. Im, Y. R., Tsui, D. W. Y., Diaz, L. A., & Wan, J. C. M. (2021). Next-generation liquid biopsies: embracing data science in oncology. Trends in Cancer, 7(4), 283-292.

Similar articles

Select your currency